Narrows FY25 Capital expenditures view to $880M-$950M from $850M-$950M. Raises FY25 GAAP effective tax rate view to 11%-13% from 9%-11%. Reaffirms non-GAAP effective tax rate view 11%-13%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron reports Q2 non-GAAP EPS $12.89, consensus $8.43
- Trump posts letters calling on drug company CEOs to lower prices
- Regeneron and Sanofi’s New COPD Study: What Investors Need to Know
- Regeneron’s Linvoseltamab Study: A New Hope for Multiple Myeloma Treatment
- Regeneron’s Mibavademab Study: A New Hope for GLD Treatment?